These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7988099)
1. Therapeutic drug monitoring and patient outcome. A review of the issues. Tonkin AL; Bochner F Clin Pharmacokinet; 1994 Sep; 27(3):169-74. PubMed ID: 7988099 [No Abstract] [Full Text] [Related]
2. The mathematics of drug dose individualization should be built with random-effects linear models. Diaz FJ; de Leon J Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456 [No Abstract] [Full Text] [Related]
3. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models". Holford NH; Buclin T Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647 [No Abstract] [Full Text] [Related]
4. Therapeutic drug monitoring in developing nations: assessing the current state of affairs in South America. Antunes MV; Linden R; Schaiquevich P Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):251-254. PubMed ID: 33276703 [No Abstract] [Full Text] [Related]
5. [Safer treatment with serum concentration monitoring of the new anticoagulants?]. Lundgaard H; Dyrkorn R; Stokes CL; Molden E; Spigset O Tidsskr Nor Laegeforen; 2016 Oct; 136(18):1556-1560. PubMed ID: 27731602 [No Abstract] [Full Text] [Related]
9. Epidemiological identification and evaluation of hepatic adverse drug reactions. Bruppacher R Semin Liver Dis; 1995 Aug; 15(3):301-8. PubMed ID: 7491508 [No Abstract] [Full Text] [Related]
10. [Pharmacogenetics, therapeutic drug monitoring and non compliance]. Stieffenhofer V; Hiemke C Ther Umsch; 2010 Jun; 67(6):309-15. PubMed ID: 20512752 [TBL] [Abstract][Full Text] [Related]
11. [The electronic health record is important in monitoring adverse drug effects]. Qvist N; Nybo M Ugeskr Laeger; 2015 Jan; 177(4):V66930. PubMed ID: 25613206 [No Abstract] [Full Text] [Related]
12. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients]. Tréluyer JM Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957 [TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Di Maio M; Basch E; Bryce J; Perrone F Nat Rev Clin Oncol; 2016 May; 13(5):319-25. PubMed ID: 26787278 [TBL] [Abstract][Full Text] [Related]
14. Development and clinical gains of nurse-led medication monitoring profiles. Gabe ME; Jordan SE J Nurs Manag; 2014 Apr; 22(3):331-49. PubMed ID: 23701013 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development. Momper JD; Wagner JA Clin Pharmacol Ther; 2014 Feb; 95(2):138-40. PubMed ID: 24253660 [TBL] [Abstract][Full Text] [Related]
16. Discontinuing drug treatments. Gnjidic D; Le Couteur DG; Hilmer SN BMJ; 2014 Nov; 349():g7013. PubMed ID: 25416561 [No Abstract] [Full Text] [Related]
17. Adverse drug reactions in children. Fiechtner H S D J Med; 1994 Sep; 47(9):325. PubMed ID: 7973598 [No Abstract] [Full Text] [Related]
18. [Drug safety: from development to clinical use]. Ovchinnikova EA; Gerasimov VB Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417 [No Abstract] [Full Text] [Related]
19. [Safety of medicinal products and reporting of adverse drug reactions]. Skibicka I; Maciejczyk A Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675 [TBL] [Abstract][Full Text] [Related]
20. Australia needs a better system for health care evaluation. Stanley FJ; Meslin EM Med J Aust; 2007 Mar; 186(5):220-1. PubMed ID: 17391080 [No Abstract] [Full Text] [Related] [Next] [New Search]